Efficacy and Safety of Durvalumab Plus Olaparib Versus Durvalumab Monotherapy in Stage IV Non-Small Cell Lung Cancer Post-Platinum Chemotherapy
- Trial ID
- 2024-512769-16-00
- Protocol
- D9102C00001
- Sponsor
- AstraZeneca AB
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to evaluate the **efficacy** of durvalumab plus olaparib combination therapy compared with durvalumab monotherapy in terms of progression-free survival (PFS) as assessed by investigators. This is clinically relevant as it aims to determine whether the combination therapy can provide a more effective maintenance treatment for patients with Stage IV non-small cell lung cancer (NSCLC) whose tumors lack EGFR mutations and ALK fusions, potentially leading to improved patient outcomes.
Secondary objectives include:
- Further assessment of the efficacy of the combination therapy compared with monotherapy in terms of overall survival (OS), objective response rate (ORR), and duration of response (DoR).
- Evaluation of PFS in the homologous recombination repair mutation (HRRm) population.
- Assessment of the pharmacokinetics (PK) of durvalumab in combination with olaparib.
- Evaluation of disease-related symptoms and health-related quality of life (HRQoL) in patients treated with the combination therapy compared to monotherapy.
- Investigation of the immunogenicity of durvalumab.
- Assessment of the safety and tolerability profile of the combination therapy compared with monotherapy.
Participants
The clinical trial involves a total of **247 participants** diagnosed with **Stage IV Non-Small Cell Lung Cancer** (NSCLC) whose tumors lack EGFR mutations and ALK fusions. The study population includes both male and female subjects, with age categories ranging from adults to the elderly. Participants were selected based on specific criteria, including a histological or cytological confirmation of Stage IV NSCLC, a performance status of 0 or 1 according to the World Health Organization (WHO) or Eastern Cooperative Oncology Group (ECOG) scale, and no prior chemotherapy or systemic therapy for Stage IV NSCLC. The trial also considers individuals with adequate organ and marrow function and those who have not received blood transfusions in the past 28 days. Participants must have at least one measurable tumor lesion that has not been previously irradiated. The ability to swallow whole oral medications is required, and individuals with gastrointestinal illnesses are excluded. The trial population includes vulnerable groups, ensuring a comprehensive assessment of the efficacy of the combination therapy under investigation.
Plans and Procedures
The clinical trial is a **Phase II randomized, double-blind, controlled study** designed to evaluate the efficacy and safety of a combination therapy of **durvalumab** and **olaparib** compared to durvalumab monotherapy. The trial targets patients with **Stage IV non-small cell lung cancer** (NSCLC) whose tumors lack EGFR mutations and ALK fusions. The study is structured to include multiple centers globally and aims to assess progression-free survival (PFS) as the primary endpoint, with secondary endpoints including overall survival (OS), objective response rate (ORR), and duration of response (DoR). The trial is expected to run from February 2019 to February 2026.
Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as documented Stage IV NSCLC, absence of prior systemic therapy for Stage IV NSCLC, and adequate organ function. Following successful screening, participants will be randomized to receive either the combination therapy or monotherapy. The trial includes regular follow-up visits to monitor treatment response and safety, with assessments conducted using RECIST 1.1 criteria. The end-of-study visit will occur upon completion of the treatment period or earlier if disease progression or unacceptable toxicity is observed.
The expected length of participant involvement is determined by the treatment period, which may extend up to 999 days, depending on individual response and tolerance. Conditions that may lead to early termination from the study include disease progression, adverse events, or withdrawal of consent. Participants will receive either oral **Lynparza** (olaparib) or intravenous **IMFINZI** (durvalumab) as per their assigned treatment group. The trial is designed to maintain blinding by using identical packaging for the investigational products. The study aims to provide valuable insights into the potential benefits of combining durvalumab with olaparib in the maintenance treatment of advanced NSCLC.
Treatment
The clinical trial involves the administration of **Lynparza** (olaparib) 150 mg film-coated tablets as part of the experimental treatment regimen. Olaparib is a chemical compound used in the study as a maintenance therapy for patients with stage IV non-small cell lung cancer. The pharmaceutical form of Lynparza is a film-coated tablet, and it is administered orally. The maximum daily dose of olaparib is 300 mg, divided into two doses of 150 mg each, taken twice daily. The tablets are provided in a blinded format, with a green film coat and no commercial debossing or marking, to maintain the integrity of the placebo-controlled study design. The treatment period for olaparib is set to a maximum of 999 days, with compliance monitored through regular assessments.
In addition to olaparib, the trial also includes the administration of **IMFINZI** (durvalumab) 50 mg/mL concentrate for solution for infusion. Durvalumab is a human monoclonal antibody of the immunoglobulin G1 kappa class, used as a monotherapy or in combination with olaparib. The pharmaceutical form is a solution for infusion, administered intravenously. The maximum daily dose of durvalumab is 1500 mg, with the infusion schedule determined by the study protocol. The specific clinical batch of durvalumab used in the trial is prepared to ensure consistency and reliability of the results. The treatment period for durvalumab is also set to a maximum of 999 days, with participant compliance monitored through infusion records and regular follow-up visits.
Efficacy
The efficacy of the clinical trial will be assessed by comparing the combination therapy of durvalumab plus olaparib with durvalumab monotherapy in patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) who have not progressed following standard platinum-based chemotherapy. The primary endpoint for evaluating efficacy is **Progression-Free Survival (PFS)**, defined as the time from randomization until objective radiological disease progression or death, as assessed by the investigator using RECIST 1.1 criteria.
Secondary endpoints include **Overall Survival (OS)**, which measures the time from randomization until death by any cause, and **Objective Response Rate (ORR)**, which is the percentage of patients achieving a complete response (CR) or partial response (PR) post-randomization. The **Duration of Response (DoR)** will also be evaluated, defined as the time from the first documented response until progression or death. Additional assessments include PFS in the homologous recombination repair mutation (HRRm) population, concentration of durvalumab, disease-related symptoms, and health-related quality of life (HRQoL) changes using EORTC QLQ-C30 and QLQ-LC13 scales, presence of anti-drug antibodies (ADA) for durvalumab, and safety endpoints such as adverse events, physical examinations, laboratory findings, and vital signs.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation (according to version 8 of the IASLC Staging Manual in Thoracic Oncology; IASLC Staging Manual in Thoracic Oncology 2016)
- Patients must have tumors that lack activating EGFR mutations and ALK fusions.
- (WHO)/(ECOG)performance status of 0 or 1
- No prior chemotherapy or any other systemic therapy for Stage IV NSCLC
- Adequate organ and marrow function without blood transfusions in the past 28 days
- At least 1 tumor lesion, not previously irradiated, that can be accurately measured as perRECIST 1.1. Key Inclusion criteria for randomization to maintenance treatment
- Documented radiographic evidence of CR, PR, or SD as per Investigator-assessed RECIST1.1 following 4 cycles of platinum-based chemotherapy.
- CrCl ≥51 mL/min calculated by the investigator or designee using the Cockcroft-Gault equation or measured by 24-hour urine collection.
- Ability to swallow whole oral medications. Patients not having GI illnesses Please refer to the protocol for rest of inclusion criteria
Exclusion Criteria
- Mixed small-cell lung cancer and sarcomatoid variant NSCLC histology
- Prior exposure to any chemotherapy agents (except chemotherapy or chemoradiation for non-metastatic disease), PARP therapy, or immune-mediated therapy
- Active or prior documented autoimmune or inflammatory disorders
- Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of IP
- untreated (CNS) metastases and/or carcinomatous meningitis
- Active infection
- Exclusion criteria to be randomized to maintenance treatment: • Inability to complete 4 cycles of platinum-based chemotherapy for any reason or discontinuation of durvalumab during initial therapy. Please refer to the protocol for rest of exclusion criteria
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Poland | Not Recruiting | 28 Feb 2019 | 80 |
Sites & Investigators
Research sites
Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
Lynparza 150 mg film-coated tablets | Comparator | FILM-COATED TABLETS | ORAL USE | 300 | 999 | PRD6152224 |
IMFINZI 50 mg/mL concentrate for solution for infusion. | Test | CONCENTRATE FOR SOLUTION FOR INFUSION | INTRAVENIOUS INFUSION | 1500 | 999 | PRD6651398 |

